JAMESBURG, N.J., June 7 /PRNewswire/ -- Phytomedics Inc., a clinical stage biopharmaceutical company developing a novel portfolio of drugs and consumer products solely derived from plant sources, announces the appointment of Dr. Jacques-Pierre Moreau to its board of directors.
"We are honored to have an experienced industry veteran of Dr. Moreau's caliber join the Phytomedics board of directors," said Dr. Laurie Smaldone MD, President and CEO of Phytomedics Inc. "Dr. Moreau is an internationally recognized expert in therapeutic agents of natural origins and is an extremely valuable addition to the Phytomedics team."
Dr. Moreau brings broad industry experience across the spectrum of discovery, development and commercialization of novel products for treatment of diverse diseases including endocrine disorders, neurologic diseases and cancer. During his career, Dr. Moreau has been involved in several successful biotech transactions and has originated and conducted R&D programs leading to the approval and commercial sales of both NCEs and botanical extracts with novel mechanisms of action. Most recently Dr. Moreau served for the past 10 years as Chief Scientific Officer of Ipsen and is known for pioneering work in the development of Ginkgo Biloba extracts for the treatment of cognitive disorders presently marketed internationally.
"I am looking forward to being an active board member at Phytomedics, as it makes its transition into late stage clinical development and commercialization," said Dr. Moreau. "With my own experience in research and development of pharmaceutical grade botanical therapeutics over the last decade, I am excited about the blockbuster potential of Phytomedics late stage drug candidates such as PMI-001 for RA, as well as the many other novel products in its portfolio."
About Phytomedics Inc.
Phytomedics Inc. is a clinical stage biopharmaceutical company with a novel portfolio of drugs and consumer products solely derived from plant sources. Through this proprietary technology platform, the Company has produced a broad pipeline of lead product candidates, several of which are in clinical development. The company's lead candidate, PMI-001, is a novel, oral, disease modifying anti-rheumatic drug currently being developed as a natural pharmaceutical alternative in rheumatoid arthritis therapy. Founded by Professor Ilya Raskin, Ph.D., presently the company's Chief Scientific Officer, Phytomedics Inc. conducts most of its discovery activities at the Biotech Center of Rutgers University.
SOURCE Phytomedics Inc.